Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories

Digestive Diseases and Sciences
C N WilliamsJ A Aquino

Abstract

Patients with active distal proctitis received either 5-aminosalicylic (5-ASA) acid or identical placebo suppositories, 500 mg t.i.d. for 6 weeks. Activity at 3 and 6 wks was assessed using a Disease Activity Index (DAI), derived from four categories: number of daily evacuations more than usual, evacuations containing blood, sigmoidoscopy appearance, and physician's overall assessment. Each category was graded 0-3. There was thus 0-12 points scored ranging from complete remission to severe disease. A minimum score of 3 from two categories was necessary for study entry. Of 27 patients randomized, 14 received active medication and 13 placebo. Of the 14 patients, with initial mean DAI 7.1 +/- 1.8, 11 were in complete remission at 6 wks (78.6%). Whereas, there was no significant change in the placebo group, with initial mean DAI 7.1 +/- 1.8. An additional 6 patients with inflammatory bowel disease and 6 healthy volunteers were given 99mTc-labelled 5-aminosalicylic acid suppositories. The extent of spread was limited to the rectum, and the suppositories were retained for 3 hours. There was no absorbed radioactivity. 5-ASA suppositories are safe, well-tolerated, and effective treatment for active distal proctitis.

References

Nov 1, 1976·Clinical Pharmacokinetics·K M Das, R Dubin
May 1, 1983·The Journal of Pharmacy and Pharmacology·M J DewJ Rhodes
Jan 1, 1980·Scandinavian Journal of Gastroenterology·C P WilloughbyS C Truelove

❮ Previous
Next ❯

Citations

Nov 15, 2001·Clinical Pharmacokinetics·M Schwab, U Klotz
Apr 1, 2006·Alimentary Pharmacology & Therapeutics·R Bergman, M Parkes
Jan 22, 2010·The Cochrane Database of Systematic Reviews·John K MarshallE Jan Irvine
May 15, 2013·Asia Pacific Allergy·Jung Hyun KimChoon-Sik Park
Sep 9, 2017·The Cochrane Database of Systematic Reviews·Vipul JairathBrian G Feagan
Jun 1, 1995·Alimentary Pharmacology & Therapeutics·J K Marshall, E J Irvine
Mar 1, 1996·Journal of Clinical Gastroenterology·F CasellasJ R Malagelada
Feb 1, 1996·Alimentary Pharmacology & Therapeutics·M G Griffin, P B Miner
Aug 5, 2000·The American Journal of Gastroenterology·J K Marshall, E J Irvine
Mar 16, 2002·Comprehensive Therapy·Daniel A LombardiSamir A Shah
Sep 12, 2006·Alimentary Pharmacology & Therapeutics·P GionchettiM Campieri
Dec 5, 2015·Expert Opinion on Drug Delivery·John Youshia, Alf Lamprecht
Dec 1, 1992·Digestive Diseases and Sciences·M CampieriL Barbara
Jun 6, 2002·Alimentary Pharmacology & Therapeutics·P GionchettiM Campieri
Sep 21, 2004·Journal of Gastroenterology and Hepatology·Cengizhan YigitlerMesut Pekcan
Jul 30, 2014·Inflammatory Bowel Diseases·Mitchell R K L LieC Janneke van der Woude
Apr 1, 1991·Scandinavian Journal of Gastroenterology·B A JacobsenS N Rasmussen
Aug 1, 1997·Alimentary Pharmacology & Therapeutics·P GionchettiM Campieri
Mar 24, 1998·Diseases of the Colon and Rectum·P GionchettiM Campieri
Aug 5, 2000·The American Journal of Gastroenterology·S HanauerM Robinson
Sep 9, 2004·Alimentary Pharmacology & Therapeutics·P GionchettiM Campieri
Apr 2, 2021·Gut·Bénédicte CaronLaurent Peyrin-Biroulet
Mar 1, 1997·Baillière's Clinical Gastroenterology·F Richter, W Scheppach
Nov 24, 2004·Advanced Drug Delivery Reviews·Altamash I Qureshi, Russell D Cohen
Mar 1, 1992·Baillière's Clinical Gastroenterology·R J Polson, J J Misiewicz
Mar 1, 2015·Gastroenterology·Subrata Ghosh, Marco Daperno

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.